George Casey

Practice Areas

George is Global Chairman of Corporate based in New York. He is recognized as one of the leading M&A practitioners and regularly advises Boards of Directors and management of major companies on strategic M&A transactions, corporate governance, ESG and shareholder relations issues.

George has extensive experience in U.S. domestic and cross-border M&A transactions, ranging from public company deals to complex carve-out sales, spin-offs, acquisitions, strategic investments and joint venture transactions, representing many of the largest U.S. and non-U.S. corporate and investment banking clients.

George combines a very diverse transactional experience with a deep understanding of clients’ businesses across the chemicals, industrials, healthcare, mining and metals, media, cable, technology and telecommunications industries, representing leading multinational corporate clients and sovereign wealth funds.

George has been inducted by Legal 500 into the Corporate/M&A “Hall of Fame,” one of 21 M&A lawyers across the United States who were awarded this recognition and was named a “Dealmaker of the Year” and “Transatlantic Corporate Dealmaker” by the American Lawyer for his transactional work. George has been included in the 2023 Legal 500 M&A Powerlist: USA and was named by clients as one of nine M&A “Super All-Stars” in the 2021 survey of U.S. M&A lawyers by BTI Consulting.

In addition to his work with clients, George is an Adjunct Professor at the University of Pennsylvania Law School where he teaches a course on mergers and acquisitions. He is also a regular lecturer on U.S. M&A at l’ École de Droit de la Sorbonne – Université Paris I. George serves as a member of the Board of Trustees of the American College of Greece.

Personal

https://www.linklaters.com/en-us/find-a-lawyer/george-casey

Work Highlights

George’s recent deal highlights include advising:

• The Dow Chemical Company in its transaction with DuPont involving US$130bn combination of the two companies and separating them into three publicly trading entities and the resulting US$50bn spin-off of Dow Inc.; its US$5bn Reverse Morris Trust transaction with Olin; its negotiations of the US$17.4bn K-Dow joint venture with PIC of Kuwait and in the ensuing arbitration over PIC's refusal to close in which Dow was awarded and was paid US$2.16bn in damages and costs; in its US$4.8bn strategic ownership restructuring of Dow Corning; the US$1.5bn sale of its MEGlobal joint venture interest to EQUATE; its US$1.63bn auction sale of Styron to Bain Capital; its US$1.67bn auction sale of Morton Salt to K+S Aktiengesellschaft; its auction sale of the global polypropylene business to Braskem; and its divestiture of the Calcium Chloride business to Occidental Petroleum.

• LANXESS in its US$1.075bn acquisition of Emerald Kalama Chemical.

• Celanese in its US$11bn acquisition of DuPont’s Mobility & Materials business; in its restructuring of its 50/50 Korea Engineering Plastics Co. joint venture with Mitsubishi Gas Chemical Company, Inc.; and in its US$1.575bn divestiture of its interest in its Polyplastics joint venture to Daicel Corporation.

• Liberty Global in its acquisition of a 4.92% stake in Vodafone Group Plc; its US$9.3bn spin-off of Liberty Latin America; its US$8.2bn acquisition of Cable & Wireless Communications plc; its US$23.3bn acquisition of Virgin Media in a stock and cash merger transaction; and its investment in Lions Gate Entertainment and on the creation of its tracking stock under English law for operations in Latin America and the Caribbean.

• GlaxoSmithKline in its US$5.1bn acquisition of Tesaro.

• LyondellBasell in its US$2.25bn acquisition of A. Schulman.

• Novartis in its US$3.9bn acquisition through a tender offer of Advanced Accelerator Applications S.A.; in “white knight” offer for Aventis in connection with an unsolicited offer for Aventis by Sanofi; US$2.5bn auction sale of the Medical Nutrition business to Nestlé; and auction sale of its Nutrition & Santé business to a private equity buyer.

• Nokia in its sale of the HERE digital mapping business to a consortium comprised of Audi AG, BMW Group and Daimler AG; and in its US$8.1bn acquisition of NAVTEQ.

• Special Committee of the Board of Directors of Amneal Pharmaceuticals in an acquisition of Kashiv Specialty Pharmaceuticals.

• The Chefs’ Warehouse in its acquisition of Chef Middle East.

• invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited, in connection with its tender offer for F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, for approximately US$161m.